Drama Ebola Scenario: Sarepta Therapeutics Inc. (SRPT), iBio Inc. (IBIO) |
Posted: October 17, 2014 |
American Video Teleconferencing Corp. (AVOT) AVOT has two (2) sub-company operations known as, Roxzu and AVOTube. Roxzu ( www.roxzu.com ) in development stage, is an on-line e-commerce coupon distribution channel and marketplace for merchants to create brand awareness for their business. Roxzu is focusing first on restaurants and dining but has plans to expand the application to include auto repairs, Realtor, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community. AVOTube ( www.avotube.com ) is a video-sharing hosting service that allows user to upload videos to share for exposure, branding, marketing and advertising. Crown Equity Holdings Inc. (CRWE) CRWE has executed a Letter of Intent to acquire AVOT. The proposed acquisition will be a stock transaction in which CRWE will acquire 95% of AVOT’s outstanding shares. CRWE is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of website communities. CRWE has included the City of Middletown, NY ( www.middletown.ny.crwe-pr.com ) to the CRWE Network. Downtown Middletown has a shopping strip and several malls along the eastern edge of the city. Excellent dining opportunities are also available in this area. The downtown area also has a number of historic churches and many large Victorian houses can be found along Highland Avenue. Apart from these, the city and its adjoining areas also offer good opportunities for biking and hiking. Middletown, NY, with an estimated population in 2013 (U.S. Census Bureau) of approximately 27,783, represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally With the addition of the city of Middletown, NY, the CRWE Network has reached the 1410th community website in the U.S., associated with 3292 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada. The geo-location based mobile marketing application Roxzu is expected to be integrated in all the CRWE Network. CRWE and PolarWeb Media, LLC reported a Joint Venture agreement to engage in increasing web traffic to selected websites. CRWE will receive 50% of the revenues generated by PolarWeb Media through the use of the CRWE Network, with PolarWeb Media having the remaining 50%. PolarWeb Media, LLC will focus on driving traffic and generating ad revenues. Online video is quickly becoming one of the most popular forms of content on the Internet. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** Ebola is a viral illness of which the initial symptoms can include a sudden fever, intense weakness, muscle pain and a sore throat. And that is just the beginning: subsequent stages are vomiting, diarrhoea and – in some cases – both internal and external bleeding. Ebola virus is spread through direct contact with bodily fluids from an infected person. During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients. The worst outbreak of Ebola virus in history, has killed about 4,500 people so far, mostly in Liberia, Guinea and Sierra Leone. International agencies and governments are fighting to contain the Ebola epidemic. According to the World Health Organization (WHO), a major outbreak of Ebola in in North America and elsewhere in Western Europe is unlikely given the strong health systems. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, died from the disease last week. Nina Pham, a nurse at Texas Health Presbyterian Hospital in Dallas, is the first patient to have contracted the deadly virus while on U.S. soil. She helped care for Thomas Eric Duncan. Amber Joy Vinson, a nurse who had cared for Thomas Eric Duncan, also had contracted the disease. Amber Joy Vinson traveled by air from Cleveland to Dallas on Oct. 13, with a low-grade fever, a day before she showed up at the hospital reporting symptoms. Several schools in Ohio and Texas shut their doors over concerns that she traveled on a plane with people with ties to the schools U.S. President Barack Obama said the likelihood of a widespread Ebola outbreak was "very, very low", and he has vowed that his administration would respond in a "much more aggressive way" to cases of Ebola in the United States. President Obama might appoint an “Ebola czar” to manage the government’s response to the deadly virus as anxiety grew over the air travel of an infected nurse. * Sarepta Therapeutics, Inc. (SRPT) SRPT reported the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. The study results are to be published in the November issue of the American Society for Microbiology’s journal, Antimicrobial Agents and Chemotherapy and are available online at www.dx.doi.org/10.1128/AAC.03442-14 AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers (PMOs AVI-7537 and AVI-7539), which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, (AVI-7287 and AVI-7288), which target the viral proteins VP24 and NP, respectively. These drug candidates use SRPT’s advanced and proprietary PMOplus(R) chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288. SRPT believes these promising early clinical safety results, coupled with the strong safety and efficacy data generated from animal studies for all four PMO compounds, reinforce the use of SRPT’s PMOplus(R) chemistry platform to pursue potential treatments for deadly infectious diseases such as Ebola and Marburg. SRPT is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. More about Sarepta Therapeutics, Inc. (SRPT) at www.sarepta.com. ** iBio, Inc. (IBIO) IBIO confirmed the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus. IBIO has offered to assist the U.S. government by making its proprietary technology available for emergency use to enable the manufacture and yield optimization of certain experimental antibody-based drugs that address the current Ebola virus outbreak, to the extent such assistance is requested by the government. IBIO owns the iBioLaunch(TM) platform, which is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. More about iBio, Inc. (IBIO) at www.ibioinc.com. ** Disclaimer: The assembled information disseminated by CRWE-PR Finance is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Crown Equity Holdings Inc. (CRWE) will receive 50% of the revenues generated by PolarWeb Media through the use of CRWE’s sites, with PolarWeb Media having the remaining 50%. Entire Disclaimer at www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|